相关实验视频

Updated: Jan 15, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

小儿肺动脉高血压中的尿路白血素E4:一个试点病例控制研究

Hamdy El-Sayed¹, Hala Elmarsafawy², Basma Shouman³

¹Department of Pediatrics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie

|October 8, 2025

概括

在患有肺动脉高血压 (PAH) 的儿童中,尿液中的白血素E4 (LTE4) 水平显著升高. 这一发现表明LTE4在PAH发展中起着作用,为这种严重疾病提供了潜在的生物标志物.

科学领域:

儿童心脏病学儿童心脏病学
肺高血压研究肺高血压研究
炎症调解者炎症调解者

背景情况:

儿科肺动脉高血压 (PAH) 是一种严重的,危及生命的疾病.
目前针对儿科PAH的向治疗方法有限.
了解潜在的发病因子对于开发新疗法至关重要.

研究的目的:

调查白血E4 (LTE4),一种炎症调解剂,在儿科肺动脉高血压 (PAH) 病变发生过程中的作用.
评估尿液LTE4水平作为儿科PAH的潜在诊断标志物.

主要方法:

该研究包括21名通过心脏导管诊断出1组PAH的儿科患者,其中许多患者患有相关的先天性心脏病 (PAHCHD).
一个由21名健康个体组成的对照组根据年龄和性别进行了匹配.
尿中的LTE4水平使用酶相关免疫吸收试验 (ELISA) 来量化.

主要成果:

与健康对照组相比,患有儿科PAH的患者在尿液中表现出明显更高的LTE4水平和LTE4/肌素比率 (p <0.05).
尿液LTE4在预测PAH方面表现出高灵敏度和特异性,截止值为35.4ppg/ml.
升高的LTE4表明它参与了儿童PAH的基础炎症过程.

结论:

儿科PAH患者尿液LTE4水平显著升高表明其作为疾病发病的炎症媒介的潜在作用.
LTE4可以作为一个有价值的生物标志物,用于早期检测和管理儿科肺动脉高血压.
对LTE4向疗法的进一步研究可能为儿科PAH提供新的治疗途径.

关键词:

遗传性心脏病是一种先天性心脏病.炎症炎症是一种炎症.叶科特E4 叶科特E4 叶科特肺动脉高血压是肺动脉高血压.

更多相关视频

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Published on: March 21, 2021

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

相关概念视频

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...